independent findings could increase the availability of tissue for corneal
transplants. A University of California, San Diego-led team has
created a new source of limbal stem cells-which are needed for clear vision-by
expressing PAX6 in skin epithelial cells, while a Harvard Medical School-led group showed
that the ATP-binding cassette transporter ABCB5 is a marker for selection of limbal
stem cells with enhanced regenerative potential.1,2
AstraZeneca's acquisition of Almirall's respiratory assets should buy time until other compounds in the pharma's pipeline mature.
For MannKind to recoup its investment, Sanofi must make good on its bet that Afrezza can succeed where Pfizer's Exubera failed.
Neoantigenics is developing diagnostics and therapeutics against oocyte-specific antigens to kill cancer cells while sparing fertility.
GestVision's rapid urine-based test uses amyloid measures to detect preeclampsia in the point of care setting.
IPOs are rewarding Flagship for sticking to its focus on novel, early stage platform plays.
Denmark's Forward Pharma is readying a U.S. push with NASDAQ IPO and confrontation with Biogen Idec in MS.
Handicapping valuation of a potential IPO by cancer immunotherapy play. Plus: TVM says FAAH; Intercept; Rigel; Achillion; Basilea; Dendreon; Insmed et al.
EMA accepted for review an MAA for ceftolozane/tazobactam from Cubist Pharmaceuticals Inc. (NASDAQ:CBST) to treat complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs). A decision is expected in 2H15. In June, FDA granted Priority...
With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies may consider targeting the cause of the wasting disease rather than its symptoms. Two independent academic teams have now found evidence that browning of white fat is responsible for cachexia in patients with cancer and propose different strategies to block the process.
AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground in scientific leadership. The company hopes to tap into world-class research through partnerships with nearby institutes.
Two independent findings could increase the availability of tissue for corneal transplants. A UCSD team has identified key factors needed to culture the limbal stem cells necessary for clear vision. A Harvard team has found a marker for enhanced regenerative potential of limbal stem cells and licensed the antibody to stem cell companies Rheacell and Ticeba.
Creating potent and orally bioavailable macrocycles is more challenging than developing small molecules, but a trio of studies could close the gap by proposing new design guidelines, identifying protein-protein interfaces to target and providing a new method to synthesize cyclic peptides.
Preventing tumor regrowth with FASN inhibitors; promoting wound healing with OR2AT4 activators; treating glaucoma with CASP8 inhibitors; and more...
A gold plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes; a Camta1-deficient mouse model of ataxia and neurodegenerative disease; a gastric tumor classification system; and more...